Delivery Order SPE2DB22D9206-SPE2DB25FV5CR

Award Date 3/24/25
Potential Completion Date 4/14/25
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price delivery order, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides for the purchase of EXPAREL 266 MG/20 ML VIAL 20ML. The order, valued at $9,948.88, has a completion date of July 25, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA...
This is a $24,872.20 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the delivery of EXPAREL 266 MG/20 ML VIAL 20ML and has a completion date of May 23, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,507.22 contract is for the delivery of EXPAREL 133 MG/10 ML VIAL 10ML, a pharmaceutical product, with a period of performance through April 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of EXPAREL 133 MG/10 ML VIAL 10ML, a pharmaceutical product, to support the recurring medical supply needs of military health facilities. The contract has a ceiling value of $14,278.20 and will run through June 21, 2024. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, with a ceiling value of $2,488.11, is for the supply of EXPAREL 266 MG/20 ML VIAL 20ML and has a period of performance through June 8, 2023. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $14,928.66, is for the delivery of EXPAREL, a 266 mg/20 ml vial pharmaceutical product, with a performance period through March 9, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,488.11 contract is for the delivery of EXPAREL 266 MG/20 ML VIAL 20ML, a medication, to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue...
The Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of EXPAREL 133 MG/10 ML VIAL 10ML. The delivery order, valued at $5,711.28, has a completion date of May 30, 2024 and was awarded on May 8, 2024. DMS Pharmaceutical Group holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued up to $499,999,999, that allows the agency to issue delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $14,928.66 award is for the supply of EXPAREL 266 MG/20 ML VIAL 20ML, with a completion date of March 31, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery orders for...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,063.78 contract is for the supply of EXPAREL 266 MG/20 ML VIAL 20ML, a pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued...
  • SPE2DB22D9206
    Indefinite Delivery Contract
  • SPE2DB22D9206-SPE2DB25FV5CR
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of EXPAREL 266 MG/20 ML VIAL 20ML. The contract has a ceiling value of $12,053.55 and an ultimate completion date of April 14, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

Generated 7/1/25, 8:17 AM